New fda-approved labeling for petros pharmaceuticals' stendra (avanafil) now includes efficacy data regarding use in men who have undergone radical prostatectomy

Expanded stendra labeling now includes data on a significant population of men not previously included following submission of additional clinical trial data new york, ny / accesswire / october 25, 2022 / petros pharmaceuticals, inc. (nasdaq:ptpi), a leading provider of therapeutics for men's health, today announces the expansion of the fda labeling for its oral erectile dysfunction (ed) drug, stendra® (avanafil), marketed by its subsidiary, metuchen pharmaceuticals. the expanded label now includes positive clinical trial data on stendra® (avanafil) use by men with ed who have undergone radical prostatectomy.
PTPI Ratings Summary
PTPI Quant Ranking